ReviewJournal for immunotherapy of cancer2013
Primer on tumor immunology and cancer immunotherapy.
Review in Journal for immunotherapy of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.PloS one · 2016Pooled it
- A Catalogue of Altered Salivary Proteins Secondary to Invasive Ductal Carcinoma: A Novel In Vivo Paradigm to Assess Breast Cancer Progression.Scientific reports · 2016Trial
- [Side effects of immune checkpoint inhibitors : Focus on pulmonary events].Radiologie (Heidelberg, Germany) · 2026Review
- Local delivery of accutoxJournal of translational medicine · 2024Article
- XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells.Cell reports · 2024Article
- Mechanism and Application Prospects of NLRC3 Regulating cGAS-STING Pathway in Lung Cancer Immunotherapy.International journal of medical sciences · 2024Review
- Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.Autoimmunity reviews · 2023Review
- The new progress in cancer immunotherapy.Clinical and experimental medicine · 2023Review
- A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC.Oncoimmunology · 2023Article
- Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer.Cancers · 2022Review
- Cancer immunotherapy: A comprehensive appraisal of its modes of application.Oncology letters · 2021Review
- Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines.Cancer gene therapy · 2021Review
- New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene.Molecules (Basel, Switzerland) · 2021Review
- Pan-Cancer Study on Protein Kinase C Family as a Potential Biomarker for the Tumors Immune Landscape and the Response to Immunotherapy.Frontiers in cell and developmental biology · 2021Article
- Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review.Journal of Cancer · 2021Article
- Role of Immunotherapy in Advanced Gastroesophageal Cancer.Current oncology reports · 2020Review
- New Aspects of Ultrasound-Mediated Targeted Delivery and Therapy for Cancer.International journal of nanomedicine · 2020Review
- Challenge of immune-mediated adverse reactions in the emergency department.Emergency medicine journal : EMJ · 2019Article
- Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.Journal of clinical medicine research · 2019Review
- Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients.Therapeutics and clinical risk management · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individualized cancer therapy is a central goal of cancer biologists. Immunotherapy is a rational means to this end-because the immune system can recognize a virtually limitless number of antigens secondary to the biology of genetic recombination in B and T lymphocytes. The immune system is exquisitely structured to distinguish self from non-self, as demonstrated by anti-microbial immune responses. Moreover the immune system has the potential to recognize self from "altered-self", which is the case for cancer. However, the immune system has mechanisms in place to inhibit self-reactive responses, many of which are usurped by evolving tumors. Understanding the interaction of cancer with the immune system provides insights into mechanisms that can be exploited to disinhibit anti-tumor immune responses. Here, we summarize the 2012 SITC Primer, reviewing past, present, and emerging immunotherapeutic approaches for the treatment of cancer-including targeting innate versus adaptive immune components; targeting and/or utilizing dendritic cells and T cells; the role of the tumor microenvironment; and immune checkpoint blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.